Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Aimee Merino, Hayden Hamsher, Daniel Mansour, Gregory I. Berk, Martin Felices, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 8851–8852.

https://doi.org/10.1182/blood-2022-162566

Published: 2022

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Blood (2022) 140 (Supplement 1): 282–283.

https://doi.org/10.1182/blood-2022-165782

Published: 2022

Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141606

Published: 2020

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-142419

Published: 2020

Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136398

Published: 2020

Journal Articles

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Kate Dixon, PhD, Robert Hullsiek, Kristin Snyder, Zachary Davis, PhD BS, Melissa Khaw, Tom Lee, PhD, Hui-Yi Chu, PhD, Ramzey Abujarour, PhD, Jason Dinella, PhD, Paul Rogers, PhD, Ryan Bjordahl, PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD, Jianming Wu, PhD, Bruce Walcheck, PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-139760

Published: 2020

Journal Articles

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Karrune Woan, MD PhD, Zachary Davis, PhD BS, Greg Bonello, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Tom Lee, PhD, Martin Felices, PhD, Bruce Walcheck, PhD, Bruce R. Blazar, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-137138

Published: 2020

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

Murali Janakiram, MD, Ravi Vij, MBBS, David S. Siegel, MD PhD, Ted Shih, PharmD, Sara Weymer, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137715

Published: 2020

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Heather Stefanski, MD PhD, Claudio G Brunstein, MD PhD, David H. McKenna, MD, Darin Sumstad, MLS, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Glen D. Raffel, MD PhD, John C. Davis, Jr., MD MPH, MS, John E. Wagner, MD

Blood (2019) 134 (Supplement_1): 804.

https://doi.org/10.1182/blood-2019-122329

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia

Hyun Don Yun, MD, Dawn Schirm, Martin Felices, PhD, Jeffrey S. Miller, MD, Craig E. Eckfeldt, MD PhD

Blood (2018) 132 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2018-99-113004

Published: 2018

Journal Articles

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Dan S Kaufman, MD PhD, Ryan Bjordahl, PhD, Huang Zhu, PhD, Robert Blum, Andres Bahena, Sajid Mahmood, PhD, Greg Bonello, PhD, Tom Lee, PhD, Bruce Walcheck, PhD, Frank Cichocki, PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2018) 132 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2018-99-113701

Published: 2018

NARROW

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia

Off-the-Shelf Natural Killer Cells with Multi-Functional Engineering Using a Novel Anti-CD19 Chimeric Antigen Receptor Combined with Stabilized CD16 and IL15 Expression to Enhance Directed Anti-Tumor Activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only